My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Jon Batiste shared a positive update on his wife Suleika Jaouad's health following her September 2024 announcement that she'd ...

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...